BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
BICYCLE THERAPEUTICS PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.54+0.08 (+2.17%)
Close on Oct 19, 2026
- Market cap
- $246.76M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-340.4%+159.7 pts over 5 years
Net margin
-301.7%+189.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +105.8% | +71.2% | +47.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -54.1% | -31.2% | |
| Return on assets | – | -37.6% | -26.2% | |
| Current ratio | – | 6.73 | 11.98 | |
| Debt to equity | – | 0.15 | – | |
| Net debt to EBITDA | – | 2.40× | – | |
| Interest coverage | – | -113.7× | -1199.3× | |
| Capex to revenue | – | 11.5% | 3.2% | |
| Diluted shares | – | 19M | 69M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bicycle Therapeutics generated $575.93M from operations and spent $27.53M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$575.93M
Used
$27.53M
Capital expenditure$27.53M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-301.7%
×Asset turnover0.09×
×Equity multiplier1.19×
=Return on equity, FY2025-31.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -301.7% | 0.09× | 1.19× | -31.2% |
| FY2024 | -479.2% | 0.05× | 1.33× | -29.0% |
| FY2023 | -669.7% | 0.05× | 1.57× | -56.3% |
| FY2022 | -779.3% | 0.03× | 1.44× | -36.5% |
| FY2021 | -571.2% | 0.04× | 1.45× | -30.3% |
| FY2020 | -491.0% | 0.08× | 1.44× | -54.1% |
| FY2019 | -221.8% | 0.14× | 8.21× | -261.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$218.96M
- Cash generatingOperating cash flow above zero-$249.68M
- Return on assets improvedROA up on the prior year-28.4% → -22.9%
- Earnings backed by cashOperating cash flow above net income-$249.68M vs -$218.96M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose13.81 → 11.98
- No dilutionShare count did not rise58M → 69M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.06 → 0.08